News | March 20, 2009

Endologix Powerlink Suprarenal Extension Trial Releases Preliminary Outcomes

March 20, 2009 - Endologix Inc. yesterday announced the first presentation of initial outcomes with up to two-year patient follow-up from its Powerlink Suprarenal Proximal Extension trial; the Powerlink System is for the minimally invasive treatment of abdominal aortic aneurysms (AAA).
The outcomes were presented at the Society for Clinical Vascular Surgery’s 37th Annual Symposium in Ft. Lauderdale, FL and delivered by principal investigator and lead enroller Stuart A. Harlin, M.D., FACS of Sacred Heart Medical Center in Pensacola, FL.
The prospective, multicenter, single-arm trial was performed in eight U.S. clinical sites. All 44 enrolled patients received the Powerlink infrarenal bifurcated stent graft via anatomical fixation at the native bifurcation, with concomitant placement of the suprarenal proximal extension to achieve proximal seal. Of the patients enrolled, 93 percent had one or more hostile aortic neck anatomical characteristics, including a high degree of angulation, presence of severe thrombus, or reverse tapering. Results include mid-term follow-up for up to two years.
Key outcomes and follow-up results from the trial include:
- 100% technical success
- No aneurysm rupture
- No conversion to open surgical repair
- No migration
- Excellent device performance and integrity with no stent fracture, no ePTFE graft failure, and no Type III or Type IV endoleak;
- 93 percent survival at one year, with no aneurysm-related mortality;
- >90 percent of patients at one year with a stable or significantly reduced aneurysm sac diameter
“One challenge with endovascular aortic repair in a patient having complex aortic neck anatomy is obtaining an effective proximal seal. In this trial, the anatomically fixed Powerlink bifurcated stent graft coupled with the suprarenal proximal extension proved highly effective in this patient group. The superb outcomes in this trial demonstrate that this treatment algorithm and device offers physicians and their patients with AAA an excellent endovascular option,” said principal investigator Dr. Harlin.
For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init